Gatti, M.; Turrini, E.; Raschi, E.; Sestili, P.; Fimognari, C.
Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals 2021, 14, 738.
https://doi.org/10.3390/ph14080738
AMA Style
Gatti M, Turrini E, Raschi E, Sestili P, Fimognari C.
Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals. 2021; 14(8):738.
https://doi.org/10.3390/ph14080738
Chicago/Turabian Style
Gatti, Milo, Eleonora Turrini, Emanuel Raschi, Piero Sestili, and Carmela Fimognari.
2021. "Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues" Pharmaceuticals 14, no. 8: 738.
https://doi.org/10.3390/ph14080738
APA Style
Gatti, M., Turrini, E., Raschi, E., Sestili, P., & Fimognari, C.
(2021). Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals, 14(8), 738.
https://doi.org/10.3390/ph14080738